OLE molecule restores microglia's protective function
A team of researchers from Spain's Institute for Neurosciences and Switzerland's EPFL has identified a molecule that can restore the brain's natural defenses against Alzheimer's disease. The compound, called OLE, appears to 'reprogram' microglia — the brain's resident immune cells — back to a protective state. In healthy brains, microglia patrol for and clear toxic proteins, but in Alzheimer's they become chronically inflamed and lose this ability.
Plaque reduction and memory improvement in animal models
In laboratory experiments on mice and worms, treatment with OLE reduced beta-amyloid plaque burden by 42% and improved memory performance on cognitive tests. The reprogrammed microglia surrounded amyloid plaques, shrank them, and helped clear them from brain tissue. The research was led by Dr. José Vicente Sánchez Mut of CSIC and Prof. Johannes Gräff of EPFL, and published in Cell Death and Disease.
New therapeutic avenue beyond plaque-targeting drugs
Current Alzheimer's drugs like lecanemab and donanemab directly target amyloid plaques, with mixed results. This microglia-reprogramming approach offers a fundamentally different strategy — instead of removing plaques directly, it restores the brain's own ability to do so. The approach also avoids some side effects of plaque-targeting antibodies, such as brain swelling. Human clinical trials are still years away, but the finding opens a new avenue for Alzheimer's treatment development.